Fol. Biol. 2016, 62, 75-81
https://doi.org/10.14712/fb2016062020075
TIMP4 Modulates ER-α Signalling in MCF7 Breast Cancer Cells
References
1. 2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283.
< , K., Dinakarpandian, D., Nagase, H. (https://doi.org/10.1016/S0167-4838(99)00279-4>
2. 2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 25, 99-113.
< , R., Liu, X. W., Jung, K. K., Kim, H. R. (https://doi.org/10.1007/s10555-006-7893-x>
3. 2014) Cell biology. Metabolic control of cell death. Science 345, 1250256.
< , D. R., Galluzzi, L., Kroemer, G. (https://doi.org/10.1126/science.1250256>
4. 2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589.
< , S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., Glass, C. K. (https://doi.org/10.1016/j.molcel.2010.05.004>
5. 2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
< , W., Sherman, B. T., Lempicki, R. A. (https://doi.org/10.1038/nprot.2008.211>
6. 2014) Protein kinase D1 regulates ERα- positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients. J. Cell. Mol. Med. 18, 2536-2552.
< , M., Bieche, I., Legay, C., Vacher, S., Auclair, C., Ricort, J. M. (https://doi.org/10.1111/jcmm.12322>
7. 2014) Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523-530.
< , A., Green, J., Pollard, J., Jr., Tugendreich, S. (https://doi.org/10.1093/bioinformatics/btt703>
8. 2012) TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J. Cell Sci. 125, 1259-1273.
< , S., Connolly, E., Smyth, J. W., Akhurst, R. J., Derynck, R. (https://doi.org/10.1242/jcs.095299>
9. 2008) TNFα-induced down-regulation of estrogen receptor-α in MCF-7 breast cancer cells. Mol. Cells 26, 285-290.
< , S. H., Nam, H. S. (https://doi.org/10.1016/S1016-8478(23)13997-5>
10. 2008) Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J. Clin. Oncol. 26, 2653-2658.
< , A., Leitzel, K., Chaudri-Ross, H. A., Evans, D. B., Ali, S. M., Demers, L., Hamer, P., Brown-Shimer, S., Pierce, K., Gaur, V., Carney, W. (https://doi.org/10.1200/JCO.2007.15.4336>
11. 2009) Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am. J. Pathol. 175, 940-946.
< , M., Sreedhar, N., Keshgegian, A., Sauter, G., Chernick, M. R., Prendergast, G. C., Wallon, U. M. (https://doi.org/10.2353/ajpath.2009.081094>
12. 2013) Estrogen-induced nongenomic calcium signaling inhibits lipopolysaccharide-stimulated tumor necrosis factor α production in macrophages. PLoS One 8, e83072.
< , L., Zhao, Y., Xie, K., Sun, X., Gao, Y., Wang, Z. (https://doi.org/10.1371/journal.pone.0083072>
13. 2005) Tissue inhibitor of metalloproteinases-4 is expressed in cervical cancer patients. Anticancer Res. 25, 623-627.
, F., Espinosa, M., Maldonado, V., Melendez-Zajgla, J. (
14. 2015a) Tissue inhibitor of metalloproteinase-4 triggers apoptosis in cervical cancer cells. PLoS One 10, 0135929.
< , F., Ceballos-Cancino, G., Espinosa, M., Vazquez- Santillan, K., Maldonado, V., Melendez-Zajgla, J. (https://doi.org/10.1371/journal.pone.0135929>
15. Lizarraga, F., Espinosa, M., Ceballos-Cancino, G., Vazquez- Santillan, K., Bahena-Ocampo, I., Schwarz-Cruz y Celis, A., Vega-Gordillo, M., Garcia-Lopez, P., Maldonado, V., Melendez-Zajgla, J. (2015b) Tissue inhibitor of metalloproteinases- 4 (TIMP-4) regulates stemness in cervical cancer cells. Mol. Carcinog. Epub ahead of print.
<https://doi.org/10.1002/mc.22442>
16. 2013) Derailed estrogen signaling and breast cancer: an authentic couple. Endocr. Rev. 34, 1-32.
< , B., Dey, O., Gajulapalli, V. N., Bhatia, R. S., Bugide, S., Kumar, R. (https://doi.org/10.1210/er.2011-1057>
17. 2008) Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol. Cancer 7, 85.
< , J., Del Pozo, L., Ceballos, G., Maldonado, V. (https://doi.org/10.1186/1476-4598-7-85>
18. 2004) Endometrial TIMP-4 mRNA is high at midcycle and in hyperplasia, but down-regulated in malignant tumours. Coordinated expression with MMP-26. Mol. Hum. Reprod. 10, 641-650.
< , R., Domanski, H., Hansson, S., Eriksson, P., Casslen, B. (https://doi.org/10.1093/molehr/gah092>
19. 2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140.
< , M. D., McCarthy, D. J., Smyth, G. K. (https://doi.org/10.1093/bioinformatics/btp616>
20. 2010) TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas. Mod. Pathol. 23, 1418-1428.
< , S., Lopez, X. M., Maris, C., Trepant, A. L., Sauvage, S., Sadeghi, N., Roland, I., Decaestecker, C., Salmon, I. (https://doi.org/10.1038/modpathol.2010.136>
21. 2013) 17β-Estradiol suppresses MHC class I chain-related B gene expression via an intact GC box. Biochem. Cell Biol. 91, 102-108.
< , N., Ponglikitmongkol, M. (https://doi.org/10.1139/bcb-2012-0072>
22. 2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 1, re6.
< , W. G. (https://doi.org/10.1126/scisignal.127re6>
23. 2012) MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res. 72, 5463-5472.
< , P., Stern-Ginossar, N., Gur, C., Glasner, A., Nachmani, D., Bauman, Y., Yamin, R., Vitenshtein, A., Stanietsky, N., Bar-Mag, T., Lankry, D., Mandelboim, O. (https://doi.org/10.1158/0008-5472.CAN-11-2671>
24. 2011) RAC3 is a pro-migratory co-activator of ERα. Oncogene 30, 1984-1994.
< , M. P., Zhang, M., Le, T. P., Wu, P., Laine, M., Greene, G. L. (https://doi.org/10.1038/onc.2010.583>
25. 2012) Effects of estrogen and progestin on expression of MMP-2 and TIMP-2 in a nude mouse model of endometriosis. Clin. Exp. Obstet. Gynecol. 39, 229-233.
, J., Ma, X. (